Market Overview

UPDATE: Maxim Group Cuts PT to $24 on ARIAD Pharmaceuticals; Label Warning Reduces Forecast

Related ARIA
Earnings Scheduled For April 12, 2017
Watch These 10 Huge Put Purchases In Tuesday Trade

Maxim Group reiterated its Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and a $24 price target.

Maxim Group said, "Unexpectedly, Iclusig's label contains a boxed warning on arterial thrombosis and hepatotoxicity. … The information suggests (1) Iclusig may have an disadvantage in competing against other CML drugs and (2) if physicians reduce dose to 15mg/day because of adverse events, Iclusig may generate smaller sales… We are reducing our peak penetration assumption to 22% from 30% to reflect potential hurdles for doctors to prescribe Iclusig. However, lower penetration is partially offset by higher-thanexpected selling price."

ARIAD Pharmaceuticals closed at $18.93 on Friday.

Latest Ratings for ARIA

Jan 2017SunTrust Robinson HumphreyDowngradesBuyHold
Jan 2017BarclaysUpgradesUnderweightEqual-Weight
Jan 2017JefferiesDowngradesBuyHold

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Maxim GroupAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!